Thrombelastographic studies on factor XIII

Thrombosis and Haemostasis

Volumn 104, Issue 6, 2010, Pages 1277-1279

  Schroeder, Verena ^a   Kohler, Hans Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN;

BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BLOOD LEVEL; DNA POLYMORPHISM; HEMOSTASIS; HUMAN; LETTER; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; FACTOR XIII; FACTOR XIII DEFICIENCY; HUMANS; PREDICTIVE VALUE OF TESTS; THROMBELASTOGRAPHY;

EID: 78649759166     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-06-0372     Document Type: Letter

References (21)

1. Theusinger OM, Baulig W, Asmis LM, et al. In vitro factor XIII supplementation increases clot firmness in rotation thrombelastometry (ROTEM). Thromb Haemost 2010: 104: 385-391.
2. McDonagh J, McDonagh RP, Delage JM, et al. Factor XIII in human plasma and platelets. J Clin Invest 1969; 48: 940-946.
3. Tyler HM. Fibrin crosslinking demonstrated by thrombelastography. Thromb Diath Haemorrh 1969; 22: 398-400.
4. Henderson KW, Nussbaum M. Mechanism of enhanced streptokinase-induced clot lysis following in-vitro factor-XIII inactivation. Br J Haematol 1969; 17: 445-453.
5. Calatzis A, Gödje O, Haas S, et al. Erhöhung der Gerinnselfestigkeit vor und nach herzchirurgischen Eingriffen durch Zusatz von Faktor XIII in vitro. In: Klinische Aspekte des Faktor-XIII Mangels. Diagnostik, klinische Relevanz, klinische Forschung. Karger 1999; pp. 55-62.
6. Glidden PF, Malaska C, Herring SW. Thrombelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost 2000; 6: 226-233.
7. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104: 467-474.
8. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12: 101-108.
9. Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 2003; 90: 434-438.
10. Nielsen VG, Gurley WQ, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99: 120-123.
11. Wettstein P, Haeberli A, Stutz M, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99: 1564-1569.
12. Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
13. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17: 75-81.
14. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25: 1247-1252.
15. Nielsen VG, Kirklin JK, Hoogendoorn H, et al. Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood Coagul Fibrinolysis 2007; 18: 145-150.
16. Weber CF, Jambor C, Marquardt M, et al. Erfassung eines Faktor-XIII-Mangels mit der Thrombelastometrie. Anaesthesist 2008; 57: 487-490.
17. Haas T, Fries D, Velik-Salchner C, et al. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008; 106: 1360-1365.
18. Dargaud Y, de Mazancourt P, Rugeri N, et al. An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy. Blood Coagul Fibrinolysis 2008; 19: 447-452.
19. 2 in whole blood from thrombocytopenic patients and healthy volunteers. Br J Haematol 2008; 143: 559-569.
20. Korte WC, Szadkowski C, Gähler A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-245.
21. Jámbor C, Reul V, Schnider TW, et al. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Aneth Analg 2009; 109: 1023-1028.